Phase II study of the predictive value of the expression of tumoral MGMT [methylguanine methyltransferase] with respect to the therapeutic response of fotemustine in patients with metastatic malignant melanoma
Phase of Trial: Phase II
Latest Information Update: 13 May 2011
At a glance
- Drugs Fotemustine (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 13 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.